Moderna to Present Data at 2024 ASCO Meeting

Moderna, Inc. recently revealed that three abstracts regarding their investigational mRNA therapy, mRNA-4157 (V940), have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 31 to June 4 in Chicago. This therapy is being developed in collaboration with Merck, recognized as MSD outside the United States and Canada.

The first abstract, titled “INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma” (Abstract #TPS9616), will be presented by Dr. Jeffrey S. Weber on Sunday, June 1. The second abstract, “The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)” (Abstract #TPS8116), will be presented by Dr. Jay M. Lee, also on June 1. The third abstract, “Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial” (Abstract #LBA9512), will be presented by Dr. Jeffrey S. Weber on Monday, June 3.

In conjunction with these presentations, Moderna will host a live webcast on June 3, from 6:15 PM to 7:15 PM CDT. This event will be accessible through the "Events and Presentations" section on Moderna’s investor website, with a replay available for 30 days post-event.

mRNA-4157 (V940) is an innovative mRNA-based individualized neoantigen therapy (INT). This treatment utilizes synthetic mRNA encoding up to 34 neoantigens, tailored based on the unique mutational profile of a patient’s tumor. When administered, these mRNA sequences are translated within the body and undergo natural cellular processing, a critical component of adaptive immunity. The goal of individualized neoantigen therapies is to stimulate a robust antitumor immune response by generating specific T-cell responses against the tumor's unique mutations. KEYTRUDA, an immunotherapy agent, enhances the body’s immune response to detect and combat cancer cells. Previous findings from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial indicated that combining mRNA-4157 (V940) with KEYTRUDA may offer significant benefits over using KEYTRUDA alone for patients with high-risk stage III/IV melanoma.

Moderna has established itself as a pioneer in mRNA medicine, significantly advancing the field through its innovative technology. This approach has revolutionized the development of treatments and vaccines, including one of the first and most effective COVID-19 vaccines. Moderna's mRNA platform has facilitated the creation of therapies for various medical conditions, such as infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. The company’s commitment to harnessing the power of science, technology, and health has enabled rapid and efficient development of new medicines.

Driven by a unique culture and a dedicated global workforce, Moderna strives to make a meaningful impact on human health through its mRNA-based treatments. The company’s core values and innovative mindset continue to guide its mission to transform medicine and deliver the highest benefits to patients worldwide.